<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666273</url>
  </required_header>
  <id_info>
    <org_study_id>18789</org_study_id>
    <secondary_id>MK-3475-920</secondary_id>
    <secondary_id>2018-000990-63</secondary_id>
    <nct_id>NCT03666273</nct_id>
  </id_info>
  <brief_title>A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254</brief_title>
  <official_title>An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the ILDR2 Function-blocking Antibody BAY1905254 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this clinical study is to determine the most appropriate dose of the
      study medication that can be safely given to cancer patients alone or in combination with
      another cancer drug, and to look at how the study medication is changed and distributed by
      the body.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 58 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 58 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of BAY1905254 after first dose administration (Cycle 1) for cohorts receiving doses ≥ 20 mg</measure>
    <time_frame>Up to 504 hours after drug in Cycle 1</time_frame>
    <description>Maximum plasma concentration after single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of BAY1905254 after first dose administration (Cycle 1) for cohorts receiving doses ≥ 20 mg</measure>
    <time_frame>Up to 504 hours after drug in Cycle 1</time_frame>
    <description>Area under the plasma concentration curve after single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BAY1905254</measure>
    <time_frame>Up to 58 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended dose of BAY1905254 for Phase 2</measure>
    <time_frame>Up to 58 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,md after multiple dosing (Cycle 3) for cohorts receiving doses ≥ 20 mg</measure>
    <time_frame>Up to 504 hours after drug in Cycle 3</time_frame>
    <description>Maximum plasma concentration after multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC after multiple dosing (Cycle 3) for cohorts receiving doses ≥ 20 mg</measure>
    <time_frame>Up to 504 hours after drug in Cycle 3</time_frame>
    <description>Area under the plasma concentration curve after multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of positive anti-drug antibody and neutralizing antibody titer for BAY1905254</measure>
    <time_frame>Up to 58 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate</measure>
    <time_frame>Up to 58 months</time_frame>
    <description>Determined by RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose escalation_Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with solid tumor types considered immunosensitive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation_Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with solid tumor types considered immunosensitive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Urothelial cancer_Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urothelial cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Urothelial cancer_Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urothelial cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion HNSCC_Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with head and neck squamous cell carcinoma (HNSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion HNSCC_Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with head and neck squamous cell carcinoma (HNSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cervical cancer_Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cervical cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Gastric cancer_Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with gastric/ gastroesophageal junction adenocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion TMB-basket_Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with immunosensitive solid tumor types having a medium-to-high tumor mutational burden (TMB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1905254</intervention_name>
    <description>Intravenous administration of escalating doses of BAY1905254 (dose escalation) or of maximum tolerated dose (expansion)</description>
    <arm_group_label>Dose escalation_Monotherapy</arm_group_label>
    <arm_group_label>Expansion Cervical cancer_Monotherapy</arm_group_label>
    <arm_group_label>Expansion HNSCC_Monotherapy</arm_group_label>
    <arm_group_label>Expansion TMB-basket_Monotherapy</arm_group_label>
    <arm_group_label>Expansion Urothelial cancer_Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1905254 + Pembrolizumab</intervention_name>
    <description>Intravenous administration of escalating doses of BAY1905254 (dose escalation) or of maximum tolerated dose (expansion), and of a fixed dose of pembrolizumab</description>
    <arm_group_label>Dose escalation_Combination therapy</arm_group_label>
    <arm_group_label>Expansion Gastric cancer_Combination therapy</arm_group_label>
    <arm_group_label>Expansion HNSCC_Combination therapy</arm_group_label>
    <arm_group_label>Expansion Urothelial cancer_Combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          -  Patients with following histologically confirmed, advanced or metastatic solid tumors
             are eligible:

               -  Dose escalation: All solid tumor types with a likelihood of sensitivity to
                  immunotherapy, as judged by the investigator.

               -  TMB-basket expansion cohort of BAY1905254 monotherapy (at MTD or MAD): patients
                  with medium-to-high TMB from selected solid tumor types with a likelihood of
                  sensitivity to immunotherapy

               -  Tumor type-specific high-dose of BAY1905254 monotherapy (at MTD or MAD) expansion
                  cohorts: urothelial cancer, HNSCC and cervical cancer with medium-to-high TMB.
                  The pre-planned tumor types may be changed based on data from the TMB-basket
                  cohort.

               -  Tumor type-specific high-dose of BAY 1905254 in combination with pembrolizumab
                  (at MTD or MAD) expansion cohorts: urothelial cancer, HNSCC and Gastric/
                  Gastroesophageal junction (GEJ) adenocarcinoma.

          -  Provision of archival tumor tissue at screening is mandatory, except for patients in
             the monotherapy TMB-basket expansion cohort.

          -  All dose expansion cohorts: Willingness to undergo paired biopsy of tumor.

          -  Patients must have received standard therapy or have no standard therapy available or
             patients have actively refused any treatment which would be regarded standard. Or, in
             the opinion of investigator have been considered ineligible for a particular form of
             standard therapy on medical grounds.

          -  Adequate bone marrow, liver and renal function.

          -  Adequate cardiac function, measured by echocardiography.

        Exclusion Criteria:

          -  History of severe immune related adverse effects from prior immunotherapy (CTCAE v.5.0
             Grade 4; CTCAE v.5.0 Grade 3 requiring treatment &gt; 4 weeks), except hypothyroidism
             clinically stable on hormone replacement treatment and controlled type 1 diabetes.

          -  Severe (CTCAE v.5.0 Grade ≥ 3) infections within 4 weeks before the first study drug
             administration, including but not limited to hospitalization for complications of
             infection, bacteremia, or severe pneumonia. Clinically active infections (CTCAE v.5.0
             &gt; Grade 1) within 2 weeks before the first study drug administration.

          -  Previous or active myocarditis/myositis in history (independent of cause)

          -  Active or history of autoimmune disease.

          -  Known human immunodeficiency virus (HIV) infection.

          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

          -  Treatment with systemic immunosuppressant medications within 2 weeks before the first
             study drug administration.

          -  Ongoing or previous anti-cancer treatment or any immunostimulatory treatment including
             but not limited to interferons (IFNs), interleukin (IL)-2 and agonists for members of
             the tumor necrosis factor (TNF) receptor superfamily (e.g. 4-1BB) within 4 weeks
             before the first study drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+)1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasm</keyword>
  <keyword>Immuno oncology drug</keyword>
  <keyword>Urothelial cancer</keyword>
  <keyword>Head and neck squamous cell carcinoma (HNSCC)</keyword>
  <keyword>Cervical cancer</keyword>
  <keyword>Gastric/ Gastroesophageal junction adenocarcinoma</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

